Lilly says its experimental GLP-1 pill better than Novo's Rybelsus in diabetes study

Eli Lilly's experimental oral drug, orforglipron, demonstrated superior efficacy in a late-stage head-to-head trial, showing greater weight loss (up to 9.2% vs. 5.3%) and better A1C reduction (up to 2.2% vs. 1.4%) compared to Novo Nordisk's oral semaglutide (Rybelsus) in patients with type 2 diabetes. This development positions Lilly strongly in the competitive oral GLP-1 market, offering a potentially more manufacturable small-molecule alternative to current injectables and intensifying the race between the two pharmaceutical giants in the lucrative cardiometabolic sector.

Analysis

Eli Lilly (LLY) has demonstrated a significant clinical and potential commercial advantage over rival Novo Nordisk (NVO) with its experimental oral drug, orforglipron. In a late-stage, head-to-head trial involving 1,698 adults, the highest dose of orforglipron achieved a 9.2% average weight loss and a 2.2% reduction in A1C. These results substantially outperform the 5.3% weight loss and 1.4% A1C reduction from the highest approved dose of Novo Nordisk's oral semaglutide. Critically, the data shows broad superiority, as even Lilly's lower dose (12 mg) outperformed Novo's highest dose on the primary endpoint of A1C reduction (1.9% vs. 1.4%). Beyond clinical efficacy, orforglipron's composition as a small-molecule pill presents a key strategic advantage, as it is inherently easier and cheaper to manufacture and package than the complex peptide-mimic injectables that currently dominate the market. This development, reflected in the extremely positive sentiment for LLY (0.8) and negative for NVO (-0.6), strongly positions Lilly in the race to launch a highly effective oral obesity treatment, pending requisite FDA approval.

Key Decisions for Investors

• Investors should view these trial results as a significant de-risking event for Eli Lilly's pipeline, which strengthens its competitive moat in the high-growth cardiometabolic market and supports a bullish outlook on the stock.
• Holders of Novo Nordisk should re-evaluate the competitive threat to its oral GLP-1 franchise, as orforglipron's superior efficacy could pressure future market share and pricing for Rybelsus and its pipeline successors.
• The primary forward-looking catalyst is the FDA submission timeline for orforglipron; its potential manufacturing advantages as a small-molecule drug could enable a more rapid and scalable market launch than existing injectables, representing a key factor for valuation.